Marketing before patenting: Implications for price controls in Canada

Open Medicine

Volumn 4, Issue 3, 2010, Pages

  Lexchin, Joel ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956037091     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Pharmaceutical price regulation scheme. Annexe K: international survey of pharmaceutical pricing and reimbursement schemes. Office of Fair Trading; 2007. Available: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885k.pdf (accessed 2010 Mar 30).
2. Abraham J. Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008. J Health Polit Policy Law 2009;34(6):931-977.
3. Department of Health. New long-term arrangements for reimbursement of generic medicines: Scheme M. London (UK): The Department; 2005. Available: http://www.dh.gov.uk/prod_consum_ dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4114256.pdf (accessed 2010 Mar 30).
4. Patented Medicine Prices Review Board. Annual report 2008. Ottawa: The Board; 2009.
5. Khoo K, Ragaz J, Hryniuk W, Gowing J, Savage C. Cancer drug access in Canada. Cancer Advocacy Coalition of Canada Report Card 2005. 2006;8(Winter):26-38. Available: http://www.canceradvocacy. ca/reportcard/2005/REPORT_CARD_2005.pdf (accessed 2010 Mar 30).
6. Patent dedication-board decision. Patented Medicine Prices Review Board Bulletin. Issue 17, Oct. 1995.